Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Delaware Health News Online.
Press releases published on August 5, 2025
Thérapeutique Knight annonce la soumission réglementaire au Mexique de CREXONT® (carbidopa et lévodopa) en capsules à libération prolongée
GlobeNewswire
·
August 5, 2025
MONTRÉAL, 05 août 2025 (GLOBE NEWSWIRE) -- Thérapeutique Knight inc. (TSX : GUD) (« Knight »), société pharmaceutique spécialisée panaméricaine (hors États-Unis), a annoncé aujourd’hui que sa filiale mexicaine, Grupo Biotoscana de Especialidad S.A. de C.V …
Palvella Therapeutics to Participate in the Canaccord Genuity 45th Annual Growth Conference
GlobeNewswire
·
August 5, 2025
WAYNE, Pa., Aug. 05, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA) Palvella Therapeutics, Inc. (Palvella), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic …
Surgery Partners, Inc. Announces Second Quarter 2025 Results
GlobeNewswire
·
August 5, 2025
BRENTWOOD, Tenn., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Surgery Partners, Inc. (NASDAQ:SGRY) (“Surgery Partners” or the “Company”), a leading short-stay surgical facility owner and operator, today announced results for the second quarter ended June 30, 2025. …
Flare Therapeutics Announces Initiation of Phase 1B Study of FX-909 for Treatment of Metastatic Urothelial Cancer
GlobeNewswire
·
August 5, 2025
CAMBRIDGE, Mass., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Flare Therapeutics Inc. (FlareTx), a clinical-stage biotechnology company targeting transcription factors to discover precision medicines for oncology and other therapeutic areas, today announced that it …
Neuronetics Reports Second Quarter 2025 Financial and Operating Results
GlobeNewswire
·
August 5, 2025
Delivered $38.1 million total revenue in the quarter, representing 18% adjusted pro forma revenue growth Generated record Greenbrook clinic revenue of $23.0 million in the quarter Reduced cash used in operations to $3.5 million, beating guidance of under $ …
Cartesian Therapeutics Announces New Employment Inducement Grants
GlobeNewswire
·
August 5, 2025
FREDERICK, Md., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the granting of inducement awards to two …
SynOx Therapeutics Completes Enrollment in Registrational Phase 3 TANGENT Clinical Trial Significantly Ahead of Timeline
GlobeNewswire
·
August 5, 2025
DUBLIN and OXFORD, United Kingdom and PHILADELPHIA, Aug. 05, 2025 (GLOBE NEWSWIRE) -- SynOx Therapeutics Limited (“SynOx”), a late-stage clinical biopharmaceutical company developing emactuzumab for Tenosynovial Giant Cell Tumours (TGCT), today announced …
AC Immune Reports Second Quarter 2025 Financial Results and Provides a Corporate Update
GlobeNewswire
·
August 5, 2025
AC Immune Reports Second Quarter 2025 Financial Results and Provides a Corporate Update Three active immunotherapies for precision prevention of neurodegeneration progressing through Phase 2 clinical development ACI-7104.056 anti-alpha-synuclein active …
MoonLake Immunotherapeutics Reports Second Quarter 2025 Financial Results and Provides a Business Update
GlobeNewswire
·
August 5, 2025
Phase 3 VELA program in hidradenitis suppurativa (HS) on track for an expected primary endpoint readout around September 2025 and an expected submission of a Biologic License Application (BLA) in the United States in mid-2026 Other clinical trials of …
Envision Pharma Group appoints Tom Langan as Chief Executive Officer
GlobeNewswire
·
August 5, 2025
Envision Pharma Group appoints Tom Langan as Chief Executive Officer Leading industry executive with 30 years’ of experience providing technology-enabled solutions to life sciences companies Fairfield, Connecticut, USA, and Horsham, United Kingdom - August …
Elicio Therapeutics Announces Positive Recommendation by IDMC to Continue ELI-002 7P Randomized Phase 2 Study in Pancreatic Cancer Without Modifications to Final Analysis
GlobeNewswire
·
August 5, 2025
The AMPLIFY-7P study of ELI-002 7P successfully passes event-driven interim analysis for efficacy, futility, and safety by the IDMC The Company views the IDMC’s positive recommendation as an indication that ELI-002 7P has shown preliminary signals of …
Foghorn Therapeutics Provides Second Quarter 2025 Financial and Corporate Update
GlobeNewswire
·
August 5, 2025
FHD-909 (LY4050784) Phase 1 dose escalation trial in SMARCA4 (BRG1) mutated cancers, with non-small cell lung cancer (NSCLC) as the primary target population, is enrolling well and remains on track Preclinical synergistic benefit of FHD-909 in combination …
Sagimet Biosciences to Participate in the Canaccord Genuity 45th Annual Growth Conference
GlobeNewswire
·
August 5, 2025
SAN MATEO, Calif., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that management …
Madrigal Pharmaceuticals Reports Second-Quarter 2025 Financial Results and Provides Corporate Updates
GlobeNewswire
·
August 5, 2025
Second-quarter 2025 Rezdiffra™ (resmetirom) net sales of $212.8 million As of June 30, 2025, more than 23,000 patients on Rezdiffra Received new U.S. Rezdiffra patent providing protection to Feb. 4, 2045 Announced global licensing agreement for an oral GLP …
Tango Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights
GlobeNewswire
·
August 5, 2025
– First patient dosed in combination trial of TNG462 and Revolution Medicines RAS(ON) inhibitors – – First patient dosed in Phase 1/2 trial with TNG456, a brain-penetrant MTA-cooperative PRMT5 inhibitor in development for glioblastoma – BOSTON, Aug. 05, …
Orchestra BioMed Secures Over $111 Million in Proceeds and Committed Capital Following Completion of Strategic Transactions and Concurrent Public and Private Equity Offerings
GlobeNewswire
·
August 5, 2025
$56.2 million in proceeds from completed public offering and concurrent private equity purchase by Medtronic and Ligand $55 million in proceeds and funding commitments from royalty-based, non-dilutive investments from Medtronic and Ligand Proceeds extend …
Boundless Bio Reports Second Quarter 2025 Financial Results and Business Highlights
GlobeNewswire
·
August 5, 2025
BBI-355 and BBI-825 combination arm of the POTENTIATE trial is now open for enrollment BBI-940 is on track for submission of an investigational new drug application in the first half of 2026 $127 million in cash supports operations into the first half of …
Ocular Therapeutix™ Reports Second Quarter 2025 Financial Results and Business Highlights
GlobeNewswire
·
August 5, 2025
Outstanding patient retention and clinical execution in complementary AXPAXLI™ SOL trials for wet AMD SOL-1 remains on track for 1Q 2026 topline data SOL-R rescue criteria streamlined and simplified with topline data expected in 1H 2027 Planning to …
Vera Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results
GlobeNewswire
·
August 5, 2025
On track to submit a Biologics License Application (BLA) for accelerated approval of atacicept to U.S. FDA in Q4 2025; potential commercial launch in 2026 Announced positive primary endpoint results from the ongoing ORIGIN Phase 3 trial Initiated the …
Axogen, Inc. Reports Second Quarter 2025 Financial Results
GlobeNewswire
·
August 5, 2025
ALACHUA, Fla. and TAMPA, Fla., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today reported financial results and …